Jefferies Group's PTGX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 5,000 shares of Protagonist Therapeutics, Inc. (PTGX) worth $436,700, representing 0.00% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in PTGX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 860,000 shares. Largest reduction occurred in Q1 2025, reducing 857,602 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Protagonist Therapeutics (PTGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Protagonist Therapeutics (PTGX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -816,503 | Reduce 99.39% | 5,000 | $87.34 |
| Q3 2025 | -2,516 | Reduce 0.31% | 821,503 | $66.43 |
| Q2 2025 | +192,126 | Add 30.40% | 824,019 | $55.27 |
| Q1 2025 | -857,602 | Reduce 57.58% | 631,893 | $48.36 |
| Q4 2024 | -325,201 | Reduce 17.92% | 1.49 M | $38.60 |
| Q3 2024 | -225,865 | Reduce 11.07% | 1.81 M | $45.00 |
| Q2 2024 | +860,000 | Add 72.85% | 2.04 M | $34.65 |
| Q1 2024 | -90,000 | Reduce 7.08% | 1.18 M | $28.93 |
| Q4 2023 | +435,000 | Add 52.06% | 1.27 M | $22.93 |
| Q3 2023 | +75,000 | Add 9.86% | 835,561 | $16.68 |
| Q2 2023 | +760,561 | New Buy | 760,561 | $27.62 |
| Q1 2023 | -100,000 | Sold Out | 0 | $0.00 |
| Q4 2022 | +100,000 | New Buy | 100,000 | $10.91 |
Jefferies Group's Protagonist Therapeutics Investment FAQs
Jefferies Group first purchased Protagonist Therapeutics, Inc. (PTGX) in Q4 2022, acquiring 100,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Protagonist Therapeutics, Inc. (PTGX) for 13 quarters since Q4 2022.
Jefferies Group's largest addition to Protagonist Therapeutics, Inc. (PTGX) was in Q2 2024, adding 2,040,561 shares worth $70.71 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 5,000 shares of Protagonist Therapeutics, Inc. (PTGX), valued at approximately $436,700.
As of the Q4 2025 filing, Protagonist Therapeutics, Inc. (PTGX) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Protagonist Therapeutics, Inc. (PTGX) was 2,040,561 shares, as reported at the end of Q2 2024.